Prophylactic use of OKT3 in liver transplantation. A review.
Liver rejection in the era of cyclosporine-based immunosuppression is approximately 60-70%. Approximately 15-25% of liver transplant patients will require hemodialysis following transplantation. These facts argue for a potent, less nephrotoxic immunosuppressive regimen, especially during the period of vulnerability to these events. Prophylactic use of OKT3 has been suggested as a means to decrease the need for hemodialysis while maintaining potent immunosuppression. The goal of this review is to examine potential benefits and pitfalls of this regimen. A lack of documentation of long-term patient and graft survival, the potential susceptibility to infectious complications, development of sensitization, and the cost must be weighed against the decreased need for hemodialysis and the control of early rejection episodes.
Department of Surgery, University of Pittsburgh, Pennsylvania 15213.
J
J
Fung
T
T
Starzl
D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D015994:Incidence; D007239:Infections / Q000453:epidemiology; D016031:Liver Transplantation; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D006435:Renal Dialysis
D016853:Muromonab-CD3